Mga Batayang Estadistika
| LEI | 549300U4G0QKK99GRT15 |
| CIK | 1629137 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Global Blood Therapeutics Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| February 14, 2023 |
GBT / Global Blood Therapeutics Inc / Deep Track Capital, LP Passive Investment SC 13G/A 1 deeptrack-gbt123122a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Global Blood Therapeutics, Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 37890U108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statemen |
|
| October 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37539 GLOBAL BLOOD THERAPEUTICS, INC. (Exact name of registrant as speci |
|
| October 5, 2022 |
Exhibit 4.1 Execution Version FIRST SUPPLEMENTAL INDENTURE FIRST SUPPLEMENTAL INDENTURE, dated as of October 5, 2022 (this ?Supplemental Indenture?), between Global Blood Therapeutics, Inc., a Delaware corporation, as issuer (the ?Company?), and U.S. Bank Trust Company, National Association (as successor in interest to U.S. Bank National Association), a national banking association organized under |
|
| October 5, 2022 |
As filed with the Securities and Exchange Commission on October 5, 2022 As filed with the Securities and Exchange Commission on October 5, 2022 Registration No. |
|
| October 5, 2022 |
As filed with the Securities and Exchange Commission on October 5, 2022 As filed with the Securities and Exchange Commission on October 5, 2022 Registration No. |
|
| October 5, 2022 |
Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF GLOBAL BLOOD THERAPEUTICS, INC. ARTICLE I The name of the corporation is: Global Blood Therapeutics, Inc. (the ?Corporation?). ARTICLE II The address, including street, number, city, and county of the registered office of the Corporation in the State of Delaware is the Corporation Trust Center, 1209 Orange Street, City of Wilmington, |
|
| October 5, 2022 |
Second Amended and Restated Bylaws of Global Blood Therapeutics, Inc., as amended on October 5, 2022 Exhibit 3.2 SECOND AMENDED AND RESTATED BY-LAWS of GLOBAL BLOOD THERAPEUTICS, INC. dated as of October 5, 2022 TABLE OF CONTENTS ARTICLE I OFFICES 1 SECTION 1. REGISTERED OFFICE 1 SECTION 2. OTHER OFFICES 1 ARTICLE II MEETINGS OF STOCKHOLDERS 1 SECTION 1. ANNUAL MEETINGS 1 SECTION 2. SPECIAL MEETINGS 1 SECTION 3. VOTING 1 SECTION 4. QUORUM 2 SECTION 5. NOTICE OF MEETINGS 2 SECTION 6. ACTION WITHOU |
|
| October 5, 2022 |
As filed with the Securities and Exchange Commission on October 5, 2022 As filed with the Securities and Exchange Commission on October 5, 2022 Registration No. |
|
| October 5, 2022 |
As filed with the Securities and Exchange Commission on October 5, 2022 As filed with the Securities and Exchange Commission on October 5, 2022 Registration No. |
|
| October 5, 2022 |
As filed with the Securities and Exchange Commission on October 5, 2022 As filed with the Securities and Exchange Commission on October 5, 2022 Registration No. |
|
| October 5, 2022 |
As filed with the Securities and Exchange Commission on October 5, 2022 As filed with the Securities and Exchange Commission on October 5, 2022 Registration No. |
|
| October 5, 2022 |
As filed with the Securities and Exchange Commission on October 5, 2022 As filed with the Securities and Exchange Commission on October 5, 2022 Registration No. |
|
| October 5, 2022 |
As filed with the Securities and Exchange Commission on October 5, 2022 As filed with the Securities and Exchange Commission on October 5, 2022 Registration No. |
|
| October 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 5, 2022 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or other jurisdiction of incorporation) (Co |
|
| October 5, 2022 |
As filed with the Securities and Exchange Commission on October 5, 2022 As filed with the Securities and Exchange Commission on October 5, 2022 Registration No. |
|
| October 5, 2022 |
As filed with the Securities and Exchange Commission on October 5, 2022 As filed with the Securities and Exchange Commission on October 5, 2022 Registration No. |
|
| October 5, 2022 |
As filed with the Securities and Exchange Commission on October 5, 2022 As filed with the Securities and Exchange Commission on October 5, 2022 Registration No. |
|
| October 5, 2022 |
As filed with the Securities and Exchange Commission on October 5, 2022 As filed with the Securities and Exchange Commission on October 5, 2022 Registration No. |
|
| October 5, 2022 |
As filed with the Securities and Exchange Commission on October 5, 2022 As filed with the Securities and Exchange Commission on October 5, 2022 Registration No. |
|
| October 5, 2022 |
As filed with the Securities and Exchange Commission on October 5, 2022 As filed with the Securities and Exchange Commission on October 5, 2022 Registration No. |
|
| September 30, 2022 |
Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2022 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or other jurisdiction of incorporation) |
|
| September 23, 2022 |
false12-31000162913700016291372022-08-072022-08-07 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| September 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| September 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| August 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| August 29, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ?? Check the appropriate box: ?? Preliminary Proxy Statement ?? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? D |
|
| August 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| August 19, 2022 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Schedule 14A (Form Type) GLOBAL BLOOD THERAPEUTICS, INC. |
|
| August 19, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ?? Check the appropriate box: ? Preliminary Proxy Statement ?? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ?? D |
|
| August 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| August 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| August 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| August 8, 2022 |
Amendment No. 1 to License Agreement by and between the Registrant and Sanofi, dated April 15, 2022 Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. EXECUTION VERSION AMENDMENT NO. 1 TO LICENSE AGREEMENT This Amendment No.1 (the ?Amendment?) to the License Agreement effective as of March 12, 2021 (the ?Agreement?) is made and entered i |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2022 GLOBAL BLOOD THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or Other Jurisdiction of Incorporation) (Com |
|
| August 8, 2022 |
Amendment to the Amended and Restated Bylaws of Global Blood Therapeutics, Inc. Exhibit 3.1 GLOBAL BLOOD THERAPEUTICS, INC. BYLAW AMENDMENT Section 8 of Article VI of the Amended and Restated Bylaws of Global Blood Therapeutics, Inc. is hereby amended and restated to read as set forth below. SECTION 8. Forum. Unless the Corporation consents in writing to the selection of an alternative forum, to the fullest extent permitted by law, (a) the Court of Chancery of the State of De |
|
| August 8, 2022 |
false12-31000162913700016291372022-08-072022-08-07 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37539 Global Blo |
|
| August 8, 2022 |
Exhibit 99.1 Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology Proposed acquisition drives growth by bringing leading sickle cell disease expertise, portfolio and pipeline to Pfizer with potential combined worldwide peak sales of more than $3 billion Potential to address the full spectrum of critical needs in the underserved sickle cell community T |
|
| August 8, 2022 |
Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER dated as of August 7, 2022 among PFIZER INC., RIBEYE ACQUISITION CORP. and GLOBAL BLOOD THERAPEUTICS, INC. TABLE OF CONTENTS Page ARTICLE I The Merger SECTION 1.01. The Merger 1 SECTION 1.02. Closing 1 SECTION 1.03. Effective Time 1 SECTION 1.04. Effects of Merger 2 SECTION 1.05. Certificate of Incorporation and By-laws 2 SECTION 1.06. Dir |
|
| July 26, 2022 |
EXHIBIT 99.1 MHRA Grants Marketing Authorization for GBT?s Oxbryta? (voxelotor) for Use in Great Britain for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older Voxelotor is the first medicine approved in Great Britain to directly inhibit sickle hemoglobin (HbS) polymerization, the underlying molecular cause of sickle cell disease SOUTH SAN FRANCISCO, Cali |
|
| July 26, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2022 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or Other Jurisdiction of Incorporation) (Comm |
|
| July 14, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2022 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or Other Jurisdiction of Incorporation) (Comm |
|
| July 14, 2022 |
GBT Initiates Expanded Access Program for Voxelotor in Patients With Sickle Cell Disease in Brazil EXHIBIT 99.1 GBT Initiates Expanded Access Program for Voxelotor in Patients With Sickle Cell Disease in Brazil SOUTH SAN FRANCISCO, Calif., July 14, 2022 (GLOBE NEWSWIRE) - Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the initiation of an expanded access program (EAP) for voxelotor in Brazil for the treatment of sickle cell disease (SCD) in adult and pediatric patients 12 y |
|
| June 29, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2022 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or Other Jurisdiction of Incorporation) (Comm |
|
| June 29, 2022 |
EXHIBIT 99.1 GBT Initiates Phase 2/3 Clinical Trial of GBT601 in Patients with Sickle Cell Disease Phase 2 portion designed to identify the optimal dose for the pivotal Phase 3 portion of the trial SOUTH SAN FRANCISCO, Calif., June 29, 2022 (GLOBE NEWSWIRE) - Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it initiated the Phase 2 portion of a planned Phase 2/3 trial of GB |
|
| June 17, 2022 |
GBT / Global Blood Therapeutics Inc / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| June 15, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2022 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or other jurisdiction of incorporation) (Comm |
|
| June 13, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2022 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or Other Jurisdiction of Incorporation) (Comm |
|
| June 13, 2022 |
EXHIBIT 99.1 New GBT Multinational Survey Shines a Needed Light on the Misunderstood Realities, Unseen Burden and Care Challenges of Sickle Cell Disease Sickle Cell Health Awareness, Perspectives and Experiences (SHAPE) survey developed with international steering committee of medical experts and patient advocates SOUTH SAN FRANCISCO, Calif., June 13, 2022 (GLOBE NEWSWIRE) - Global Blood Therapeut |
|
| June 10, 2022 |
EXHIBIT 99.1 GBT Presents Positive New Real-World Evidence Data at EHA2022 Congress Further Supporting Clinical Use of Oxbryta® (voxelotor) in Sickle Cell Disease Positive results from Phase 1 study of GBT601, including incremental new data, support advancing into planned Phase 2/3 trial by mid-year GBT to hold investor conference call and webcast today at 3:00 p.m. CEST (9:00 a.m. EDT) to highlig |
|
| June 10, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2022 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or Other Jurisdiction of Incorporation) (Comm |
|
| June 6, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2022 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or Other Jurisdiction of Incorporation) (Commi |
|
| June 6, 2022 |
EXHIBIT 99.1 GBT’s Inclacumab and GBT601 Receive U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for the Treatment of Sickle Cell Disease Inclacumab is a novel P-selectin inhibitor currently in Phase 3 clinical trials to reduce vaso-occlusive crises (VOCs) and readmissions due to VOCs in patients with sickle cell disease GBT601 is a next generation sickle hemoglobin (HbS) polymerizati |
|
| May 12, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or Other Jurisdiction of Incorporation) (Commi |
|
| May 12, 2022 |
EXHIBIT 99.1 GBT Announces Five Data Presentations on Sickle Cell Disease at Upcoming EHA2022 Congress New real-world evidence data on Oxbryta? (voxelotor) from multicenter RETRO Study and new Phase 1 data on GBT601 to be highlighted SOUTH SAN FRANCISCO, Calif., May 12, 2022 (GLOBE NEWSWIRE) - Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced five abstracts related to its sickle |
|
| May 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2022 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or Other Jurisdiction of Incorporation) (Commis |
|
| May 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37539 Global Bl |
|
| May 4, 2022 |
EXHIBIT 99.1 GBT Reports First Quarter 2022 Financial Results Achieved Oxbryta? (voxelotor) net revenues of $55.2 million in the first quarter 2022, a 41% increase year over year Strong new prescription growth driven by the recent launch for children ages 4 to less than 12 years and improving trends for patients ages 12 years and over Reinitiated GBT601 Phase 1 trial in sickle cell disease (SCD) p |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 28, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitte |
|
| March 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2022 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or other jurisdiction of incorporation) (Com |
|
| February 23, 2022 |
Amended and Restated Severance and Change in Control Policy Exhibit 10.12 Global Blood Therapeutics, Inc. Amended and Restated Severance and Change in Control Policy Adopted on July 23, 2015 (amended and restated on January 6, 2016, July 5, 2017, July 26, 2017, December 13, 2017, March 13, 2018, July 23, 2019, October 16, 2019, January 7, 2020, May 26, 2020, November 30, 2020 and January 1, 2022) Benefits in Connection with a Sale Event. In connection with |
|
| February 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37539 Global Blood |
|
| February 23, 2022 |
EXHIBIT 99.1 GBT Reports Fourth Quarter and Full Year 2021 Financial Results Achieved Oxbryta? (voxelotor) net revenues of $56.1 million in the fourth quarter and $194.7 million for full year 2021, a 57% increase year over year Executed on key growth opportunities highlighted by pediatric label expansion in the U.S., marketing authorization for ages 12 and over in the EU, and advancement of R&D pi |
|
| February 23, 2022 |
Non-Employee Director Compensation Policy Exhibit 10.16 GLOBAL BLOOD THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (the ?Policy?) of Global Blood Therapeutics, Inc., a Delaware corporation (the ?Company?), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees o |
|
| February 23, 2022 |
Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES OF REGISTRANT Not applicable. |
|
| February 23, 2022 |
Amended and Restated U.S. Cash Incentive Bonus Plan Exhibit 10.7 global blood therapeutics, INC. AMENDED AND RESTATED U.S. CASH INCENTIVE BONUS PLAN 1. Purpose This Amended and Restated U.S. Cash Incentive Bonus Plan (the ?Plan?) is intended to provide an annual incentive for superior work and to help motivate eligible U.S. employees of Global Blood Therapeutics, Inc. (the ?Company?) toward even higher achievement and business results, to further t |
|
| February 23, 2022 |
Exhibit 10.21 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH ?[***]?. AMENDED AND RESTATED LOAN AGREEMENT Dated as of December 14, 2021 among GLOBAL BLOOD THERAPEUTICS, INC. (as Borro |
|
| February 23, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2022 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or Other Jurisdiction of Incorporation) ( |
|
| February 16, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2022 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or Other Jurisdiction of Incorporation) ( |
|
| February 16, 2022 |
EXHIBIT 99.1 European Commission Approves Oxbryta? (voxelotor) for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older The first sickle hemoglobin polymerization inhibitor approved in Europe, Oxbryta increases hemoglobin levels and reduces sickling and hemolysis ? the cause of long-term complications of sickle cell disease SOUTH SAN FRANCISCO, Calif., Feb. |
|
| February 14, 2022 |
240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* (Name of Issuer) Global Blood Therapeutics, Inc. (Title of Class of Securities) Common Stock, Par Valu |
|
| February 14, 2022 |
EXHIBIT 99.1 AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of Global Blood Therapeutics, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them. February 14, 2022 BAKER BROS. ADVISORS LP By: Baker Bros. Advisors (GP) |
|
| February 14, 2022 |
GBT / Global Blood Therapeutics Inc / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* Global Blood Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 37890U 10 8 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| February 14, 2022 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessi |
|
| February 14, 2022 |
GBT / Global Blood Therapeutics Inc / BAKER BROS. ADVISORS LP - SCHEDULE 13G Passive Investment SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2022 |
EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. |
|
| February 10, 2022 |
GBT / Global Blood Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Global Blood Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 37890U108 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| January 31, 2022 |
GBT / Global Blood Therapeutics Inc / BANK OF AMERICA CORP /DE/ Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 02)* Global Blood Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 37890U108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| January 31, 2022 |
EX-FILING FEES 6 d292184dexfilingfees.htm EX-FILING FEES Calculation of Filing Fee Tables Form S-8 (Form Type) Global Blood Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount o |
|
| January 31, 2022 |
As filed with the U.S. Securities and Exchange Commission on January 31, 2022 As filed with the U.S. Securities and Exchange Commission on January 31, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GLOBAL BLOOD THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 27-4825712 (State or other jurisdiction of incorporation or organiz |
|
| January 31, 2022 |
Exhibit 99.3 GLOBAL BLOOD THERAPEUTICS, INC. AMENDED AND RESTATED 2017 INDUCEMENT EQUITY PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Global Blood Therapeutics, Inc. Amended and Restated 2017 Inducement Equity Plan (the ?Plan?). The purpose of the Plan is to enable Global Blood Therapeutics, Inc., a Delaware corporation (the ?Company?), and its Subsidiaries |
|
| January 31, 2022 |
Amended and Restated 2015 Stock Option and Incentive Plan and form agreements thereunder Exhibit 99.1 GLOBAL BLOOD THERAPEUTICS, INC. AMENDED AND RESTATED 2015 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Global Blood Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and other key |
|
| January 27, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2022 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or Other Jurisdiction of Incorporation) (C |
|
| January 27, 2022 |
EXHIBIT 99.1 Positive Early Access to Medicines Scheme (EAMS) Scientific Opinion Awarded to GBT?s Voxelotor for the Treatment of Haemolytic Anaemia Due to Sickle Cell Disease LONDON, Jan. 27, 2022 (GLOBE NEWSWIRE) - Global Blood Therapeutics (GBT) today announced that the UK?s Medicines and Healthcare products Regulatory Agency (MHRA) has awarded a positive scientific opinion under the Early Acces |
|
| January 10, 2022 |
EXHIBIT 99.1 Oxbryta? (voxelotor) Tablets for Oral Suspension, A New Dispersible Tablet Dosage Form, Now Available for Patients with Sickle Cell Disease in the United States SOUTH SAN FRANCISCO, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) - Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced Oxbryta? (voxelotor) tablets for oral suspension, a new dispersible, once-daily tablet dosage fo |
|
| January 10, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or Other Jurisdiction of Incorporation) (C |
|
| December 17, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2021 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or Other Jurisdiction of Incorporation) ( |
|
| December 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2021 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or other jurisdiction of incorporation) ( |
|
| December 17, 2021 |
EX-4.1 2 d254711dex41.htm EX-4.1 Exhibit 4.1 GLOBAL BLOOD THERAPEUTICS, INC. AND U.S. BANK NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of December 17, 2021 1.875% Convertible Senior Notes due 2028 TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS Section 1.01. Definitions 1 Section 1.02. References to Interest 13 ARTICLE 2 ISSUE, DESCRIPTION, EXECUTION, REGISTRATION AND EXCHANGE OF NOTES Sectio |
|
| December 17, 2021 |
Form of Capped Call Transaction Confirmation Exhibit 10.1 [Dealer name and address] To: Global Blood Therapeutics, Inc. 181 Oyster Point Boulevard South San Francisco, CA 94080 From: [Dealer] Re: [Base][Additional] Capped Call Transaction Date: December [], 2021 Dear Ladies and Gentlemen: The purpose of this communication (this ?Confirmation?) is to set forth the terms and conditions of the above-referenced transaction entered into on the Tr |
|
| December 17, 2021 |
EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 GBT’s Oxbryta® (voxelotor) Receives Positive CHMP Opinion for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Aged 12 Years and Older European Commission decision on marketing authorization anticipated first quarter of 2022 Oxbryta would be the first oral treatment available in Europe to directly inhibit sickle hemoglobin (HbS) |
|
| December 17, 2021 |
EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 U.S. FDA Approves Supplemental New Drug Application for Expanded Indication of Oxbryta® (voxelotor) for Children as Young as 4 Years of Age with Sickle Cell Disease New dispersible tablet dosage form also approved Oxbryta is the first medicine that addresses the root cause of red blood cell sickling SOUTH SAN FRANCISCO, Calif., Dec. 17, 2021 (GLOBE N |
|
| December 17, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2021 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or Other Jurisdiction of Incorporation) ( |
|
| December 15, 2021 |
GBT Announces Proposed Offering of $250.0 Million of Convertible Senior Notes EX-99.1 2 d275631dex991.htm EX-99.1 Exhibit 99.1 GBT Announces Proposed Offering of $250.0 Million of Convertible Senior Notes SOUTH SAN FRANCISCO, Calif. – December 14, 2021 – Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it intends to offer $250.0 million aggregate principal amount of its Convertible Senior Notes due 2028 (the “notes”) in a private offering (the “offer |
|
| December 15, 2021 |
GBT Announces Pricing of Upsized Offering of $300.0 Million of Convertible Senior Notes Exhibit 99.2 GBT Announces Pricing of Upsized Offering of $300.0 Million of Convertible Senior Notes SOUTH SAN FRANCISCO, Calif. ? December 14, 2021 ? Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the pricing of $300.0 million aggregate principal amount of its Convertible Senior Notes due 2028 (the ?notes?) in a private offering (the ?offering?) to persons reasonably believed |
|
| December 15, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2021 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or other jurisdiction of incorporation) ( |
|
| December 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2021 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or other jurisdiction of incorporation) ( |
|
| December 13, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2021 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or other jurisdiction of incorporation) ( |
|
| December 13, 2021 |
EX-99.1 2 d270260dex991.htm EX-99.1 GBT021601, a Next-Generation RESULTS HbS Polymerization Inhibitor: Results of Safety, Tolerability, Healthy Volunteers Study Healthy Volunteers Study Adults Living with Pharmacokinetics and – Single Ascending Dose – Multiple Ascending Dose SCD Study Pharmacodynamics in Adults Living with Sickle Cell Disease and Design for Healthy Volunteers Study – Single Ascend |
|
| December 13, 2021 |
EXHIBIT 99.1 GBT Presents Positive Results from Phase 1 Study of GBT021601 in Patients with Sickle Cell Disease and Healthy Volunteers at ASH Annual Meeting and Exposition GBT601 demonstrated average hemoglobin occupancy of greater than 30% with 100 mg daily doses in a multiple ascending dose study of six adult SCD patients GBT601 tolerability was favorable in studies of SCD patients and healthy v |
|
| December 13, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2021 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or Other Jurisdiction of Incorporation) ( |
|
| November 4, 2021 |
EXHIBIT 99.1 GBT Announces Six Data Presentations on Sickle Cell Disease at Upcoming 63rd American Society of Hematology (ASH) Annual Meeting & Exposition Accepted Abstracts Include Real-World Experience with Oxbryta? (voxelotor) and Phase 1 Data on GBT021601 and Inclacumab SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) - Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today annou |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37539 Globa |
|
| November 4, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2021 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or Other Jurisdiction of Incorporation) (C |
|
| November 4, 2021 |
EXHIBIT 99.1 GBT Reports Third Quarter 2021 Financial Results Achieved Oxbryta? (voxelotor) net revenues of $52.1 million, a 41% increase year over year Oxbryta sNDA and NDA for pediatric label expansion accepted by FDA for priority review; PDUFA target action date of December 25, 2021 Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) - Global Blood |
|
| November 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2021 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or Other Jurisdiction of Incorporation) (C |
|
| November 4, 2021 |
EX-10.1 2 gbt-ex101.htm EX-10.1 Exhibit 10.1 June 15, 2021 Carrie Krehlik 6015 Colton Blvd. Oakland, CA 94611 Dear Carrie, Global Blood Therapeutics, Inc. (the “Company”) is pleased to offer you employment on the following terms: 1. Position. Your title will be EVP, Chief Human Resources Officer, and you will report to Ted Love, President and CEO. This is a full-time position. While you render ser |
|
| September 7, 2021 |
EXHIBIT 99.1 U.S. FDA Accepts for Priority Review Supplemental New Drug Application for Oxbryta? (voxelotor) for the Treatment of Sickle Cell Disease in Children Ages 4 to 11 New Drug Application for Oxbryta dispersible tablets also accepted for priority review Approximately 17,000 children ages 4 to 11 years have sickle cell disease in the United States SOUTH SAN FRANCISCO, Sept. 07, 2021 (GLOBE |
|
| September 7, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2021 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or Other Jurisdiction of Incorporation) ( |
|
| August 3, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| August 3, 2021 |
Exhibit 10.1 November 23, 2020 Kim M. Smith-Whitley, MD Dear Kim, Global Blood Therapeutics, Inc. (the ?Company?) is pleased to offer you employment on the following terms: 1. Position. Your title will be EVP, Head of Research & Development, and you will report to Ted Love, President and CEO. This is a full-time position. While you render services to the Company, you will not engage in any other e |
|
| August 3, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2021 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or Other Jurisdiction of Incorporation) (Com |
|
| August 3, 2021 |
EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 GBT Reports Second Quarter 2021 Financial Results Achieved Oxbryta® (voxelotor) net revenues of $47.6 million, an increase of 51% year-over-year Continued progress toward potential Oxbryta pediatric label expansion in U.S. and marketing authorization in Europe Advanced pipeline with initiation of two inclacumab pivotal Phase 3 trials and GBT021601 (G |
|
| July 22, 2021 |
EXHIBIT 99.1 GBT Provides Regulatory and Pipeline Updates in Sickle Cell Disease (SCD) Submits Supplemental New Drug Application to the U.S. FDA for Oxbryta? (voxelotor) in Children with SCD Ages 4 to 11 Initiates Phase 3 Clinical Trials of Inclacumab and Enrolls First SCD Patient in Phase 1 Study of GBT021601 SOUTH SAN FRANCISCO, Calif., July 22, 2021 (GLOBE NEWSWIRE) - Global Blood Therapeutics, |
|
| July 22, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2021 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or Other Jurisdiction of Incorporation) (Comm |
|
| June 17, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2021 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or other jurisdiction of incorporation) (Comm |
|
| June 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2021 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or Other Jurisdiction of Incorporation) (Comm |
|
| June 14, 2021 |
EXHIBIT 99.1 GBT?s Voxelotor is First Sickle Cell Disease Treatment to Receive Promising Innovative Medicine (PIM) Designation in the UK SOUTH SAN FRANCISCO, Calif. and LONDON, June 14, 2021 (GLOBE NEWSWIRE) - Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments for underserved patient comm |
|
| June 11, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2021 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or Other Jurisdiction of Incorporation) (Comm |
|
| June 11, 2021 |
EXHIBIT 99.1 New Data Supporting the Potential Use of Oxbryta? (voxelotor) in Children Ages 4 to 11 Years with Sickle Cell Disease Presented at European Hematology Association 2021 Virtual Congress Analysis from Phase 2a HOPE-KIDS 1 Study Featured in Oral Presentation Two Real-world Data Studies Demonstrated Sustained Improvements in Hemoglobin with Oxbryta Consistent with Results from the Phase 3 |
|
| May 13, 2021 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessi |
|
| May 13, 2021 |
240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.)* (Name of Issuer) Global Blood Therapeutics, Inc. (Title of Class of Securities) Common Stock, Par Value |
|
| May 12, 2021 |
EXHIBIT 99.1 GBT Announces Upcoming Data Presentations at European Hematology Association (EHA) 2021 Virtual Congress New Oxbryta? (voxelotor) Data from Phase 2a HOPE-KIDS 1 Study Demonstrate Improvement in Hemoglobin and Hemolysis in Children Ages 4 to 11 Years with Sickle Cell Disease SOUTH SAN FRANCISCO, Calif., May 12, 2021 (GLOBE NEWSWIRE) - Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) |
|
| May 12, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2021 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or Other Jurisdiction of Incorporation) (Commi |
|
| May 5, 2021 |
Table of Contents Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 5, 2021 |
License Agreement by and between the Company and Sanofi, dated March 12, 2021 Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. EXECUTION VERSION LICENSE AGREEMENT between SANOFI and GLOBAL BLOOD THERAPEUTICS Dated as of March 12, 2021 TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 ARTICLE 2 GRANT OF RIGHTS 12 2.1 |
|
| May 5, 2021 |
EXHIBIT 99.1 GBT Reports First Quarter 2021 Financial Results Achieved Oxbryta? (voxelotor) net revenues of $39.0 million; on track with plans to potentially expand access to Oxbryta in the U.S. and Europe Advanced pipeline programs inclacumab and GBT021601 (GBT601) and expanded pipeline with in-license of two novel small molecule programs Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, |
|
| May 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2021 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or Other Jurisdiction of Incorporation) (Commis |
|
| April 28, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitte |
|
| April 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| March 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2021 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or other jurisdiction of incorporation) (Com |
|
| March 16, 2021 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2021 GLOBAL BLOOD THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or other jurisdiction of incorporation) (Com |
|
| February 24, 2021 |
Subsidiaries of the Registrant EX-21.1 7 d63231dex211.htm EX-21.1 Exhibit 21.1 SUBSIDIARIES OF REGISTRANT Not applicable. |
|
| February 24, 2021 |
Non-Employee Director Compensation Policy Exhibit 10.16 GLOBAL BLOOD THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (the ?Policy?) of Global Blood Therapeutics, Inc., a Delaware corporation (the ?Company?), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees o |
|
| February 24, 2021 |
Amended and Restated 2017 Inducement Equity Plan and forms of award agreements thereunder Exhibit 10.8 GLOBAL BLOOD THERAPEUTICS, INC. AMENDED AND RESTATED 2017 INDUCEMENT EQUITY PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Global Blood Therapeutics, Inc. Amended and Restated 2017 Inducement Equity Plan (the ?Plan?). The purpose of the Plan is to enable Global Blood Therapeutics, Inc., a Delaware corporation (the ?Company?), and its Subsidiaries |
|
| February 24, 2021 |
Amended and Restated Cash Incentive Bonus Plan Exhibit 10.7 GLOBAL BLOOD THERAPEUTICS, INC. AMENDED AND RESTATED CASH INCENTIVE BONUS PLAN 1. Purpose This Amended and Restated Cash Incentive Bonus Plan (the ?Plan?) is intended to provide an annual incentive for superior work and to help motivate eligible employees of Global Blood Therapeutics, Inc. (the ?Company?) toward even higher achievement and business results, to further tie their goals |
|
| February 24, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2021 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or Other Jurisdiction of Incorporation) ( |
|
| February 24, 2021 |
EXHIBIT 99.1 GBT Reports Recent Business Progress and Fourth Quarter and Full Year 2020 Financial Results Achieved Oxbryta® (voxelotor) net revenues of $41.3 million in the fourth quarter and $123.8 million for full year 2020 Further established leadership in sickle cell disease (SCD) with data presentations on pipeline programs inclacumab and GBT021601 (GBT601) Conference call today at 4:30 p.m. |
|
| February 24, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001- |
|
| February 24, 2021 |
Amended and Restated Severance and Change in Control Policy Exhibit 10.12 Global Blood Therapeutics, Inc. Amended and Restated Severance and Change in Control Policy Adopted on July 23, 2015 (amended and restated on January 6, 2016, July 5, 2017, July 26, 2017, December 13, 2017, March 13, 2018, July 23, 2019, October 16, 2019, January 7, 2020, May 26, 2020 and November 30, 2020) Benefits in Connection with a Sale Event. In connection with a Sale Event (as |
|
| February 24, 2021 |
Amended and Restated 2015 Stock Option and Incentive Plan and forms of award agreements thereunder Exhibit 10.2 GLOBAL BLOOD THERAPEUTICS, INC. AMENDED AND RESTATED 2015 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Global Blood Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan (the ?Plan?). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and other key |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Global Blood Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 37890U 10 8 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Global Blood Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 37890U108 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 8, 2021 |
Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 01)* Global Blood Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 37890U108 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 4, 2021 |
Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2021 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or Other Jurisdiction of Incorporation) (C |
|
| February 4, 2021 |
EXHIBIT 99.1 GBT Initiates Expanded Access Protocol for Oxbryta® (voxelotor) in Pediatric Patients with Sickle Cell Disease in the United States SOUTH SAN FRANCISCO, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) - Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that an expanded access protocol (EAP) for Oxbryta® (voxelotor) in pediatric patients with sickle cell disease (SCD) has been |
|
| January 29, 2021 |
EX-99.3 Exhibit 99.3 GLOBAL BLOOD THERAPEUTICS, INC. AMENDED AND RESTATED 2017 INDUCEMENT EQUITY PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Global Blood Therapeutics, Inc. Amended and Restated 2017 Inducement Equity Plan (the “Plan”). The purpose of the Plan is to enable Global Blood Therapeutics, Inc., a Delaware corporation (the “Company”), and its Subsi |
|
| January 29, 2021 |
S-8 As filed with the U.S. Securities and Exchange Commission on January 29, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GLOBAL BLOOD THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 27-4825712 (State or other jurisdiction of incorporation or org |
|
| January 27, 2021 |
EXHIBIT 99.1 European Medicines Agency Accepts GBT’s Marketing Authorization Application (MAA) for Oxbryta® (voxelotor) for the Treatment of Hemolytic Anemia in Sickle Cell Disease SOUTH SAN FRANCISCO, Calif., Jan. 27, 2021 (GLOBE NEWSWIRE) - Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that the European Medicines Agency (EMA) has completed the validation of GBT’s Marketing |
|
| January 27, 2021 |
Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2021 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or Other Jurisdiction of Incorporation) (C |
|
| December 7, 2020 |
EXHIBIT 99.1 GBT Presents New Data on the Long-Term and Real-World Use of Oxbryta® (voxelotor) Tablets in Patients with Sickle Cell Disease at 62nd ASH Annual Meeting and Exposition Final 72-Week Analyses of Phase 3 HOPE Study Demonstrate Durable Improvements in Hemoglobin Levels and Significant Improvements in Overall Health Status Real-World Experience Study Results Consistent with HOPE Study an |
|
| December 7, 2020 |
EXHIBIT 99.2 GBT Presents Data on New Sickle Cell Disease Pipeline Therapies with Best-in-Class Potential – Inclacumab and GBT021601 Two Inclacumab Pivotal Phase 3 Clinical Trials Expected to Begin in First Half of 2021 GBT021601 – Potent Next-Generation Hemoglobin S Polymerization Inhibitor Shown to be Highly Effective in SCD Animal Models SOUTH SAN FRANCISCO, Calif., Dec. 06, 2020 (GLOBE NEWSWIR |
|
| December 7, 2020 |
Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2020 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or Other Jurisdiction of Incorporation) (C |
|
| December 2, 2020 |
Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2020 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or Other Jurisdiction of Incorporation) (C |
|
| December 2, 2020 |
EXHIBIT 99.1 GBT Initiates Early Access Program for Voxelotor in Patients with Sickle Cell Disease in Europe and Other Regions Outside the United States SOUTH SAN FRANCISCO, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) - Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the initiation of an early access program for voxelotor, in Europe and other regions outside the United States, for t |
|
| November 5, 2020 |
EXHIBIT 99.1 GBT Reports Recent Business Progress and Third Quarter 2020 Financial Results Achieved Oxbryta® (voxelotor) net revenues of $36.9 million with more than 1,000 new patient prescriptions in the third quarter and net revenues of $82.5 million through first nine months of 2020 New Oxbryta data and new research on GBT’s pipeline to be presented at the 2020 American Society of Hematology An |
|
| November 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2020 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or Other Jurisdiction of Incorporation) (C |
|
| November 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37539 Globa |
|
| November 4, 2020 |
EXHIBIT 99.1 GBT Announces Upcoming Virtual Data Presentations at 62nd American Society of Hematology (ASH) Annual Meeting & Exposition Abstracts Include 72-Week Analysis of Phase 3 HOPE Study Supporting Long-Term Use of Oxbryta® (voxelotor) Preclinical Data Highlights Promise of GBT’s Sickle Cell Disease Pipeline GBT to Host Virtual Analyst & Investor Day Event on Monday, Dec. 7, 2020 SOUTH SAN F |
|
| November 4, 2020 |
Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2020 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or Other Jurisdiction of Incorporation) (C |
|
| October 26, 2020 |
Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2020 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or Other Jurisdiction of Incorporation) (C |
|
| October 26, 2020 |
GBT Presents Data at 15th Annual Scientific Conference on Sickle Cell and Thalassemia EXHIBIT 99.1 GBT Presents Data at 15th Annual Scientific Conference on Sickle Cell and Thalassemia Real-world effectiveness data on Oxbryta® (voxelotor) in the treatment of sickle cell disease featured as oral presentation SOUTH SAN FRANCISCO, Calif., Oct. 26, 2020 (GLOBE NEWSWIRE) - Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), today announced its participation in the 15th Annual Scientif |
|
| August 7, 2020 |
S-8 As filed with the U.S. Securities and Exchange Commission on August 7, 2020 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GLOBAL BLOOD THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 27-4825712 (State or other jurisdiction of incorporation or organ |
|
| August 5, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| August 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2020 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or Other Jurisdiction of Incorporation) (Com |
|
| August 5, 2020 |
EX-10.2 Exhibit 10.2 Global Blood Therapeutics, Inc. Amended and Restated Severance and Change in Control Policy Adopted on July 23, 2015 (amended and restated on January 6, 2016, July 5, 2017, July 26, 2017, December 13, 2017, March 13, 2018, July 23, 2019, October 16, 2019, January 7, 2020 and May 26, 2020) Benefits in Connection with a Sale Event. In connection with a Sale Event (as defined in |
|
| August 5, 2020 |
Sales Agreement by and between the Registrant and SVB Leerink LLC, dated August 5, 2020 EX-1.2 Exhibit 1.2 GLOBAL BLOOD THERAPEUTICS, INC. $200,000,000 COMMON STOCK SALES AGREEMENT August 5, 2020 SVB Leerink LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: Global Blood Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with SVB Leerink LLC (“SVB Leerink”), as follows: 1. Issuance and Sale of |
|
| August 5, 2020 |
Amended and Restated 2017 Inducement Equity Plan and forms of award agreements thereunder EX-10.1 Exhibit 10.1 GLOBAL BLOOD THERAPEUTICS, INC. AMENDED AND RESTATED 2017 INDUCEMENT EQUITY PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Global Blood Therapeutics, Inc. Amended and Restated 2017 Inducement Equity Plan (the “Plan”). The purpose of the Plan is to enable Global Blood Therapeutics, Inc., a Delaware corporation (the “Company”), and its Subsi |
|
| August 5, 2020 |
S-3ASR Table of Contents As filed with the Securities and Exchange Commission on August 5, 2020 Registration No. |
|
| August 5, 2020 |
EXHIBIT 99.1 GBT Reports Recent Business Progress and Second Quarter 2020 Financial Results Achieved Oxbryta® (voxelotor) net revenues of $31.5 million, with approximately 1,000 new patient prescriptions Announced plans to seek approval of Oxbryta for younger pediatric patients in the United States and seek approval of Oxbryta in Europe Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Ca |
|
| June 24, 2020 |
EXHIBIT 99.1 GBT Announces Plans to Seek Regulatory Approval for Oxbryta® (voxelotor) to Treat Sickle Cell Patients in Europe Intends to seek full marketing authorization for Oxbryta to treat hemolytic anemia in sickle cell disease Marketing Authorization Application submission planned by mid-2021 SOUTH SAN FRANCISCO, Calif., June 24, 2020 (GLOBE NEWSWIRE) - Global Blood Therapeutics, Inc. (GBT) ( |
|
| June 24, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2020 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or Other Jurisdiction of Incorporation) (Comm |
|
| June 19, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2020 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or other jurisdiction of incorporation) (Comm |
|
| June 8, 2020 |
EXHIBIT 99.1 GBT Announces Plans to Seek Expanded Labeling for Oxbryta® (voxelotor) to Treat Children Ages 4 to 11 Years with Sickle Cell Disease New Drug Application submission, including new age-appropriate formulation, planned by mid-2021 SOUTH SAN FRANCISCO, Calif., June 08, 2020 (GLOBE NEWSWIRE) - Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced plans to expand the potentia |
|
| June 8, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2020 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or Other Jurisdiction of Incorporation) (Commi |
|
| June 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2020 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or other jurisdiction of incorporation) (Commi |
|
| May 15, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2020 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or other jurisdiction of incorporation) (Commi |
|
| May 6, 2020 |
Amended and Restated 2015 Employee Stock Purchase Plan EX-10.5 Exhibit 10.5 GLOBAL BLOOD THERAPEUTICS, INC. AMENDED AND RESTATED 2015 EMPLOYEE STOCK PURCHASE PLAN The purpose of the Global Blood Therapeutics, Inc. Amended and Restated 2015 Employee Stock Purchase Plan (the “Plan”) is to provide eligible employees of Global Blood Therapeutics, Inc. (the “Company”) and each Designated Subsidiary (as defined in Section 11) with opportunities to purchase |
|
| May 6, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| May 6, 2020 |
GBT Reports Recent Business Progress and First Quarter 2020 Financial Results EXHIBIT 99.1 GBT Reports Recent Business Progress and First Quarter 2020 Financial Results Achieved Oxbryta® (voxelotor) net revenues of $14.1 million in first full quarter of launch Approximately 1,650 new patient prescriptions for Oxbryta during the first quarter Adapted to virtual operations and engagement intended to ensure ongoing access to Oxbryta during the COVID-19 pandemic Contributed mor |
|
| May 6, 2020 |
Non-Employee Director Compensation Policy, as amended and restated on March 24, 2020 EX-10.6 Exhibit 10.6 GLOBAL BLOOD THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (the “Policy”) of Global Blood Therapeutics, Inc., a Delaware corporation (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not empl |
|
| May 6, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2020 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or Other Jurisdiction of Incorporation) (Commis |
|
| April 28, 2020 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| April 28, 2020 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 28, 2020 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| March 17, 2020 |
GBT Takes Steps to Support Public Health Efforts to Address COVID-19 Pandemic EXHIBIT 99.1 GBT Takes Steps to Support Public Health Efforts to Address COVID-19 Pandemic SOUTH SAN FRANCISCO, Calif., March 17, 2020 (GLOBE NEWSWIRE) - Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), which is focused on transforming the treatment and care of people living with sickle cell disease, today announced steps the company is taking to support public health efforts to address the CO |
|
| March 17, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2020 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or Other Jurisdiction of Incorporation) (Com |
|
| March 3, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2020 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or other jurisdiction of incorporation) (Comm |
|
| February 26, 2020 |
Subsidiaries of the Registrant EX-21.1 Exhibit 21.1 SUBSIDIARIES OF REGISTRANT Not applicable. |
|
| February 26, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2020 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or Other Jurisdiction of Incorporation) ( |
|
| February 26, 2020 |
EXHIBIT 99.1 GBT Reports Recent Business Progress and Fourth Quarter and Full Year 2019 Financial Results Obtained FDA approval of Oxbryta® (voxelotor), the first treatment that specifically targets the root cause of sickle cell disease (SCD), three months ahead of schedule Made Oxbryta available to adults and children 12 years of age and older with SCD within days of FDA approval Maintained stron |
|
| February 26, 2020 |
EX-10.20 Exhibit 10.20 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH “[***]”. Execution Copy LICENSE AND COLLABORATION AGREEMENT by and between SYROS PHARMACEUTICALS, INC. and GLOBAL BLOOD THERAPEUTICS, INC. Dated as of December 17, |
|
| February 26, 2020 |
EX-4.2 Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2019, Global Blood Therapeutics, Inc. (the “Company,” “we,” “us,” and “our”) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our Common Stock. Description of Common Stock The following d |
|
| February 26, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001- |
|
| February 26, 2020 |
EX-10.21 Exhibit 10.21 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH “[***]”. LOAN AGREEMENT Dated as of December 17, 2019 among GLOBAL BLOOD THERAPEUTICS, INC. (as Borrower), BIOPHARMA CREDIT PLC (as Collateral Agent and a Lender) a |
|
| February 14, 2020 |
GBT / Global Blood Therapeutics, Inc. / BANK OF AMERICA CORP /DE/ - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* Global Blood Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 37890U108 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| February 14, 2020 |
EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 14, 2020 PERCEPTIVE ADVISORS LLC |
|
| February 14, 2020 |
GBT / Global Blood Therapeutics, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Global Blood Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 37890U 10 8 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de |
|
| February 12, 2020 |
GBT / Global Blood Therapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Global Blood Therapeutics Inc Title of Class of Securities: Common Stock CUSIP Number: 37890U108 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| January 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Global Blood Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 37890U108 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w |
|
| January 23, 2020 |
Amended and Restated 2017 Inducement Equity Plan and forms of award agreements thereunder EX-99.3 Exhibit 99.3 GLOBAL BLOOD THERAPEUTICS, INC. AMENDED AND RESTATED 2017 INDUCEMENT EQUITY PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Global Blood Therapeutics, Inc. Amended and Restated 2017 Inducement Equity Plan (the “Plan”). The purpose of the Plan is to enable Global Blood Therapeutics, Inc., a Delaware corporation (the “Company”), and its Subsi |
|
| January 23, 2020 |
Amended and Restated 2015 Stock Option and Incentive Plan and forms of award agreements thereunder EX-99.1 Exhibit 99.1 GLOBAL BLOOD THERAPEUTICS, INC. AMENDED AND RESTATED 2015 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Global Blood Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and ot |
|
| January 23, 2020 |
GBT / Global Blood Therapeutics, Inc. S-8 - - S-8 S-8 1 d876082ds8.htm S-8 As filed with the U.S. Securities and Exchange Commission on January 23, 2020 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GLOBAL BLOOD THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 27-4825712 (State or other jurisdiction of |
|
| January 9, 2020 |
Exhibit 10.2 global blood therapeutics, INC. CASH INCENTIVE BONUS PLAN 1. Purpose This Cash Incentive Bonus Plan (the “Plan”) is intended to provide an annual incentive for superior work and to help motivate eligible employees of Global Blood Therapeutics, Inc. (the “Company”) and its subsidiaries toward even higher achievement and business results, to further tie their goals and interests to thos |
|
| January 9, 2020 |
Amended and Restated Severance and Change in Control Policy Exhibit 10.1 Global Blood Therapeutics, Inc. Amended and Restated Severance and Change in Control Policy Adopted on July 23, 2015 (amended and restated on January 6, 2016, July 5, 2017, July 26, 2017, December 13, 2017, March 13, 2018, July 23, 2019, October 16, 2019 and January 7, 2020) Benefits in Connection with a Sale Event. In connection with a Sale Event (as defined in the Global Blood Thera |
|
| January 9, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2020 GLOBAL BLOOD THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or Other Jurisdiction of Incorporation) (Co |
|
| December 18, 2019 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2019 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or Other Jurisdiction of Incorporation) ( |
|
| December 18, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2019 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or Other Jurisdiction of Incorporation) ( |
|
| November 26, 2019 |
EXHIBIT 99.1 FDA Approves Oxbryta™ (Voxelotor), the First Medicine Specifically Targeting the Root Cause of Sickle Cell Disease First and only FDA-approved sickle hemoglobin polymerization inhibitor, a new class of therapy Oxbryta broadly indicated for the treatment of sickle cell disease in adults and children 12 years of age and older1 Approval comes three months ahead of FDA’s priority review a |
|
| November 26, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 25, 2019 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or Other Jurisdiction of Incorporation) ( |
|
| November 22, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2019 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or Other Jurisdiction of Incorporation) ( |
|
| November 7, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2019 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or Other Jurisdiction of Incorporation) (C |
|
| November 7, 2019 |
GBT Reports Recent Business Progress and Third Quarter 2019 Financial Results EXHIBIT 99.1 GBT Reports Recent Business Progress and Third Quarter 2019 Financial Results SOUTH SAN FRANCISCO, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) - Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today reported recent business progress and financial results for the third quarter ended September 30, 2019. “With the recent FDA acceptance of our NDA filing for voxelotor, we are an important |
|
| November 7, 2019 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 7, 2019 |
EX-10.1 Exhibit 10.1 Global Blood Therapeutics, Inc. Change in Control Policy Adopted on July 23, 2015 (amended on January 6, 2016, July 5, 2017, July 26, 2017, December 13, 2017, March 13, 2018, July 23, 2019 and October 16, 2019) In connection with a Sale Event (as defined in the Global Blood Therapeutics, Inc. 2015 Stock Option and Incentive Plan (as may be further amended or restated, the “201 |
|
| November 6, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2019 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or Other Jurisdiction of Incorporation) (C |
|
| November 6, 2019 |
EXHIBIT 99.1 GBT Announces Upcoming Data Presentations at 61st American Society of Hematology Annual Meeting & Exposition Abstracts Include Three Post-hoc Analyses of Phase 3 HOPE Study Clinical Data Data Further Support the Safety and Efficacy of Voxelotor for Sickle Cell Disease (SCD) Examination of Real-world Evidence Further Establishes Relationship Between Higher Levels of Hemoglobin and Decr |
|
| October 21, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2019 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or Other Jurisdiction of Incorporation) (C |
|
| October 21, 2019 |
EXHIBIT 99.1 GBT Announces Results of Post-hoc Analysis of Phase 3 HOPE Study Showing Improvement in Leg Ulcers in Patients with Sickle Cell Disease Treated with Voxelotor First of Several Post-hoc Analyses Planned Using HOPE Study Clinical Data Findings Presented in Poster Session at 13th Annual Academy for Sickle Cell and Thalassemia Conference SOUTH SAN FRANCISCO, Calif., Oct. 21, 2019 (GLOBE N |
|
| September 5, 2019 |
EXHIBIT 99.1 GBT Announces U.S. Food and Drug Administration Acceptance of New Drug Application and Priority Review for Voxelotor for the Treatment of Sickle Cell Disease Priority Review Shortens FDA Review Time to Six Months from Standard 10 Months NDA Supported by Data from Phase 3 HOPE Study, which Demonstrated Statistically Significant and Sustained Improvements in Hemoglobin with Voxelotor SO |
|
| September 5, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2019 Global Blood Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37539 27-4825712 (State or Other Jurisdiction of Incorporation) ( |
|
| August 7, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 7, 2019 Global Blood Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-37539 27-4825712 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 7, 2019 |
GBT Reports Recent Business Progress and Second Quarter 2019 Financial Results EXHIBIT 99.1 GBT Reports Recent Business Progress and Second Quarter 2019 Financial Results SOUTH SAN FRANCISCO, Calif., Aug. 07, 2019 (GLOBE NEWSWIRE) - Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today reported recent business progress and financial results for the second quarter ended June 30, 2019. “We accomplished several significant milestones in the second quarter of this year, incl |
|
| August 7, 2019 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| August 7, 2019 |
Employment Offer Letter by and between the Registrant and Eric Fink, dated June 17, 2019 EX-10.1 Exhibit 10.1 June 17, 2019 Eric Fink Dear Eric, Global Blood Therapeutics, Inc. (the “Company”) is pleased to offer you employment on the following terms: 1. Position. Your initial title will be Chief Human Resources Officer, and you will report to Ted Love, Chief Executive Officer. This is a full-time position. While you render services to the Company, you will not engage in any other emp |
|
| June 28, 2019 |
EX-1.1 Exhibit 1.1 3,375,527 Shares GLOBAL BLOOD THERAPEUTICS, INC. Common Stock UNDERWRITING AGREEMENT June 26, 2019 Cantor Fitzgerald & Co. As Representative of the several Underwriters listed in Schedule 1 hereto c/o Cantor Fitzgerald & Co. 499 Park Avenue New York, New York 10022 Ladies and Gentlemen: Global Blood Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue an |
|
| June 28, 2019 |
Global Blood Therapeutics Announces Proposed Public Offering of Common Stock EX-99.1 Exhibit 99.1 Global Blood Therapeutics Announces Proposed Public Offering of Common Stock SOUTH SAN FRANCISCO, Calif., June 25, 2019 (GLOBE NEWSWIRE) — Global Blood Therapeutics, Inc. (GBT) (Nasdaq: GBT), a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities, today announced an agree |
|
| June 28, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2019 Global Blood Therapeutics, Inc. |
|
| June 28, 2019 |
Global Blood Therapeutics Prices a $200.0 Million Common Stock Public Offering EX-99.2 Exhibit 99.2 Global Blood Therapeutics Prices a $200.0 Million Common Stock Public Offering SOUTH SAN FRANCISCO, Calif., June 26, 2019 (GLOBE NEWSWIRE) — Global Blood Therapeutics, Inc. (GBT) (Nasdaq: GBT), a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities, today announced the pr |
|
| June 28, 2019 |
Global Blood Therapeutics, Inc. Amended and Restated 2017 Inducement Equity Plan EX-99.1 Exhibit 99.1 GLOBAL BLOOD THERAPEUTICS, INC. AMENDED AND RESTATED 2017 INDUCEMENT EQUITY PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Global Blood Therapeutics, Inc. Amended and Restated 2017 Inducement Equity Plan (the “Plan”). The purpose of the Plan is to enable Global Blood Therapeutics, Inc., a Delaware corporation (the “Company”), and its Subsi |
|
| June 28, 2019 |
GBT / Global Blood Therapeutics, Inc. S-8 - - S-8 S-8 As filed with the U.S. Securities and Exchange Commission on June 28, 2019 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GLOBAL BLOOD THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 27-4825712 (State or other jurisdiction of incorporation or organi |
|
| June 28, 2019 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-220127 CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered Amount to be registered(1) Maximum offering price per share Maximum aggregate offering price Amount of registration fee(2) Common stock, par value $0.001 per share 3,881,856 shares $59.25 $229,999,968.00 $27,876.00 (1) Includes 506, |
|
| June 25, 2019 |
$200,000,000 Global Blood Therapeutics, Inc. 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-220127 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to |
|
| June 20, 2019 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): June 18, 2019 Global Blood Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-37539 27-4825712 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| June 14, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): June 14, 2019 Global Blood Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-37539 27-4825712 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 10, 2019 |
Employment Offer Letter by and between the Registrant and Jung Choi, dated March 16, 2015 EX-10.1 Exhibit 10.1 GLOBAL BLOOD THERAPEUTICS, INC. 400 EAST JAMIE COURT, SUITE 101 SOUTH SAN FRANCISCO, CA 94080 March 16, 2015 Jung Choi Dear Jung, Global Blood Therapeutics, Inc. (the “Company”) is pleased to offer you employment on the following terms: 1. Position. Your initial title will be Chief Business and Strategy Officer, and you will initially report to Ted Love. This is a full-time po |
|
| May 10, 2019 |
10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 8, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 8, 2019 Global Blood Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-37539 27-4825712 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 8, 2019 |
GBT Reports Recent Business Progress and First Quarter 2019 Financial Results EXHIBIT 99.1 GBT Reports Recent Business Progress and First Quarter 2019 Financial Results SOUTH SAN FRANCISCO, Calif., May 08, 2019 (GLOBE NEWSWIRE) - Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today reported recent business progress and financial results for the first quarter ended March 31, 2019. “With a goal of getting voxelotor to the sickle cell community as quickly as possible, our |
|
| April 29, 2019 |
GBT / Global Blood Therapeutics, Inc. DEFA14A DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| April 29, 2019 |
GBT / Global Blood Therapeutics, Inc. DEFA14A DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| April 29, 2019 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 29, 2019 |
EX-10.1 Exhibit 10.1 Execution Version Confidential License Agreement This Agreement is entered into with effect as of the Effective Date (as defined below) by and between F. Hoffmann-La Roche Ltd with an office and place of business at Grenzacherstrasse 124, 4070 Basel, Switzerland (“Roche Basel”) and Hoffmann-La Roche Inc. with an office and place of business at 150 Clove Road, Suite 8, Little F |
|
| March 29, 2019 |
10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission fil |
|
| March 27, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 26, 2019 Global Blood Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-37539 27-4825712 (State or Other Jurisdiction of Incorporation) (Com |
|
| February 27, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): February 27, 2019 Global Blood Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-37539 27-4825712 (State or Other Jurisdiction of Incorporation) (Comm |
